Predictors of the need for atrioventricular nodal ablation following redo ablation for atrial fibrillation.
ablation
atrial fibrillation
atrioventricular nodal ablation
pace and ablate
pacemaker
Journal
Journal of arrhythmia
ISSN: 1880-4276
Titre abrégé: J Arrhythm
Pays: Japan
ID NLM: 101263026
Informations de publication
Date de publication:
Jun 2024
Jun 2024
Historique:
received:
30
11
2023
revised:
28
01
2024
accepted:
03
03
2024
medline:
28
6
2024
pubmed:
28
6
2024
entrez:
28
6
2024
Statut:
epublish
Résumé
Patients who have recurrent atrial fibrillation (AF) following redo catheter ablation may eventually be managed with a pace-and-ablate approach, involving pacemaker implant followed by We analyzed patients undergoing redo AF ablations between 2013 and 2019 at our institution. Follow-up was censored on December 31, 2021. Patients with no available follow-up data were excluded. Time-to-event analysis with Cox proportional hazard regression was used to compare those who underwent AVNA to those who did not. A total of 467 patients were included, of whom 39 (8.4%) underwent AVNA. After multivariable adjustment, female sex (aHR 4.68 [95% CI 2.30-9.50]; Female sex, ischemic heart disease, and persistent AF may be useful clinical predictors of the requirement for subsequent AVNA and may be considered as part of shared clinical decision making.
Sections du résumé
Background
UNASSIGNED
Patients who have recurrent atrial fibrillation (AF) following redo catheter ablation may eventually be managed with a pace-and-ablate approach, involving pacemaker implant followed by
Methods
UNASSIGNED
We analyzed patients undergoing redo AF ablations between 2013 and 2019 at our institution. Follow-up was censored on December 31, 2021. Patients with no available follow-up data were excluded. Time-to-event analysis with Cox proportional hazard regression was used to compare those who underwent AVNA to those who did not.
Results
UNASSIGNED
A total of 467 patients were included, of whom 39 (8.4%) underwent AVNA. After multivariable adjustment, female sex (aHR 4.68 [95% CI 2.30-9.50];
Conclusion
UNASSIGNED
Female sex, ischemic heart disease, and persistent AF may be useful clinical predictors of the requirement for subsequent AVNA and may be considered as part of shared clinical decision making.
Identifiants
pubmed: 38939768
doi: 10.1002/joa3.13023
pii: JOA313023
pmc: PMC11199796
doi:
Types de publication
Journal Article
Langues
eng
Pagination
501-507Informations de copyright
© 2024 The Authors. Journal of Arrhythmia published by John Wiley & Sons Australia, Ltd on behalf of Japanese Heart Rhythm Society.
Déclaration de conflit d'intérêts
DG reports: institutional research grants from Boston Scientific and Medtronic, and speaker fees from Boston Scientific. AB reports consultant or speaker fees from Medtronic. The other authors report no conflicts of interest.